Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 6/25/18

|Includes: Acorda Therapeutics, Inc. (ACOR), ADMS, BMRN, ECYT

Summary

This week's Marketplace postings include interviews with experts discussing assets from: ECYT, BMRN, ADMS, ACOR.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Evaluating the Market potential of Endocyte's Lu-PSMA-617 as a 3rd line treatment for metastatic castration-resistant prostate cancer

Ticker: ECYT

Call Date: 05/25/2018

Who's the Expert?

  • Associate Professor of Medicine, Associate Professor in Surgery, and Associate Professor in Pharmacology and Cancer Biology at Duke.
  • Treats 100-125 patients with metastatic castration-resistant prostate cancer
  • Research focuses on predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer, cancer biomarkers, and pharmacodynamic/translational studies in prostate, kidney, bladder cancer.

Interview Goal:

To discuss the market potential of Lu-PSMA-617, a radioligand therapy (RLT) being developed by Endocyte that utilizes a high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells.

Link to original project page on Slingshot Insights with questions asked: link

TRANSCRIPT 2: Exploring the market potential for BioMarin's Pegvaliase in treating phenylketonuria (PKU)

Ticker: BMRN

Call Date: 05/25/2018

Who's the Expert?

  • Director, PKU Program and Professor of Pediatrics (Genetics, Birth Defects, and Metabolism), Northwestern University Feinberg School of Medicine.

  • Currently manages 260 patients with Phenylketonuria (PKU).

  • Has participated in numerous clinical trials of new therapies for metabolic disorders including PKU, lysosomal storage disorders and fatty acid oxidation defects and has authored over 200 articles in the peer-reviewed literature.

Interview Goal:

To dig into the PKU treatment landscape and examine where Pegvaliase fits in.

Link to original project page on Slingshot Insights with questions asked: link

TRANSCRIPT 3: A Third Look: Exploring the market potential for treatments in the Parkinson's Disease Space including Gocovri with a Prescribing Physician

Ticker: ADMS, ACOR

Call Date: 05/24/2018

Who's the Expert?

  • Associate Professor of Neurology, Medical Director, Deep Brain Stimulation Program & Director of the Neurotoxin Injection Program at OHSU.
  • Currently treats 200 patients with Parkinson's Disease.
  • Research focuses on detection and neuroprotective interventions for Parkinson’s disease; member of the national Parkinson Study Group and the International Parkinson and Movement Disorder Society for over two decades.

Interview Goal: To give investors a better understanding of the success of Gocovri for PD dyskinesia since launch.

Link to original project page on Slingshot Insights with questions asked: link

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these interview and more : Link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.